Research & Regulatory News
Semaglutide in Obesity-Related Heart Failure
Kosiborod and colleagues published semaglutide in patients with heart failure with preserved ejection fraction and obesity in the New England Journal of Medicine in September 2023, followed by a pooled analysis of the STEP-HFpEF programme in the Lancet in April 2024.
Key facts
- Kosiborod 2023
- NEJM, 21 September (PMID 37622681)
- Butler 2024
- Lancet, pooled analysis (PMID 38599221)
- Population
- Obesity-related HFpEF
- Design
- Randomised, placebo-controlled
- Contrast
- Tirzepatide HFpEF data is observational
- Under regulatory review
- Reported for this indication
Why HFpEF is a distinct target
Heart failure with preserved ejection fraction is heterogeneous, and one recognised phenotype is closely tied to obesity and metabolic disease. That association makes substantial weight reduction a mechanistic hypothesis in this population specifically, rather than an opportunistic extension of an obesity drug into cardiology.
Why randomised evidence matters more here than usual
HFpEF has resisted treatment for decades, and the field carries a long record of observational associations that randomised trials failed to confirm. In that context a randomised placebo-controlled trial is not merely preferable — it is the only design the specialty is likely to accept, given how many promising associations have not survived one.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
What the pooled analysis adds
Butler and colleagues pooled the STEP-HFpEF programme in the Lancet in April 2024. Pooling related randomised trials increases precision and allows subgroup questions that individual trials are underpowered for, while keeping randomisation intact — the same advantage the gallbladder meta-analysis exploits.
How this sits beside the tirzepatide work
This site separately covers tirzepatide in HFpEF, which was studied by target trial emulation on retrospective cohort data. That design removes analytical biases but cannot balance unmeasured factors. STEP-HFpEF is randomised. Both concern HFpEF and they are not the same grade of evidence, which is a distinction usually lost when results are listed together.
What a regulatory filing does and does not mean
Semaglutide has been reported as under review for this indication. A submission means a sponsor considers the evidence sufficient to ask; it is not an approval, and the assessment is what determines whether the indication is granted and on what terms.
The boundary
Semaglutide is a licensed medicine and these were registered trials conducted under clinical supervision. Nothing supplied on this site is semaglutide, is related to it, or is an alternative to any treatment for heart failure.
Extended research context
The Research & Regulatory News deep dive
Deep dive: why 2026 was the year the incretin field split in two
For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.
Deep dive: what a marketing authorisation actually means
An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.
Deep dive: reading trial results without being misled
Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.
Research applications
- ▸Tracking regulatory status of investigational incretin compounds
- ▸Understanding the difference between authorisation, NICE appraisal and NHS availability
- ▸Comparing peptide and non-peptide receptor agonist pharmacology
- ▸Interpreting Phase 3 topline releases before peer-reviewed publication
- ▸Verifying trial identity against ClinicalTrials.gov registrations
Handling checklist
- ✓Check the compound named in a trial registration matches the compound being discussed
- ✓Confirm the NCT identifier resolves to the acronym being cited
- ✓Read topline press releases as preliminary until peer-reviewed publication
- ✓Separate the trial population from the headline percentage before comparing studies
- ✓Treat authorisation in one jurisdiction as saying nothing about status in another
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Treating a positive Phase 3 as approval
Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.
✗ Comparing weight-reduction percentages across different trials
Fix: Population, duration and comparator differ; the numbers are not interchangeable.
✗ Assuming one incretin's approval legitimises another compound
Fix: Authorisations are product-specific and do not transfer between compounds.
✗ Citing a TRIUMPH number without checking the NCT identifier
Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.
✗ Reading research material as an alternative to a licensed medicine
Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is orforglipron a peptide?
- Has retatrutide been approved by the MHRA?
- What did TRIUMPH-1 actually report?
- Why can orforglipron be taken as a tablet when peptides cannot?
- Are research peptides legal in the UK?
- What is the difference between MHRA authorisation and NHS availability?
Frequently asked questions
- Why study a weight-loss drug in heart failure?
- One recognised HFpEF phenotype is closely associated with obesity and metabolic disease, which makes substantial weight reduction a mechanistic hypothesis.
- How does this differ from the tirzepatide HFpEF data?
- STEP-HFpEF is randomised and placebo-controlled. The tirzepatide work used target trial emulation on retrospective cohort data — a weaker design.
- Is it approved for heart failure?
- It has been reported as under regulatory review for the indication. A submission is a request for assessment, not an approval.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedKosiborod MN et al., Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity — NEJM 2023 (PMID 37622681)pubmed.ncbi.nlm.nih.gov
- PubMedButler J et al., Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis — Lancet 2024 (PMID 38599221)pubmed.ncbi.nlm.nih.gov
- PubMedLin YM et al., Effectiveness of tirzepatide in HFpEF using target trial emulation — Nat Commun 2025 (PMID 40368924)pubmed.ncbi.nlm.nih.gov
- RefMHRA · Medicines and Healthcare products Regulatory Agencygov.uk
- RefNICE · National Institute for Health and Care Excellencenice.org.uk
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066) — Retatrutide pivotal obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · ATTAIN-1 (NCT05869903) — Orforglipron in obesity/overweightclinicaltrials.gov
- RefEli Lilly · TRIUMPH-1 topline results (May 2026)investor.lilly.com
- PubMedOrforglipron: A Comprehensive Review — Int J Mol Sci 2026 (PMID 41683830)pubmed.ncbi.nlm.nih.gov
- RefMHRA Yellow Card — report a defective or falsified medicineyellowcard.mhra.gov.uk
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More Research & Regulatory News articles
- STRIDE and the Qualifier That Keeps Getting DroppedA phase 3b randomised trial of semaglutide in symptomatic PAD — and type 2 diabetes. The diabetes criterion is in the title and rarely survives summary.
- A Trial That Had to Move Two Things at Once407 participants, Phase 3, with co-primary endpoints of body weight and WOMAC pain score. Published in NEJM in October 2024.
- A Nationwide Cohort, and a Result That Points Away From the DrugDanish registries, 2009 to 2023. Preterm birth risk was raised in the diabetes indication but not in weight management — which is the finding.
- Canada in January, India in MarchCanada became the first G7 nation where semaglutide patents expired, on 4 January 2026. India followed in March, with generics reported at 70–90% discounts.
- Two Pathways, Two TimescalesA generic drug shows bioequivalence. A biosimilar shows no clinically meaningful difference. The 40-residue line decides which applies.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchHow the Incretin Field Got Here
- GHK-Cu (Copper Peptide)Copper Tripeptide-1: The Cosmetic Ingredient Name
- TB-500 (Thymosin β4 fragment)TB-500 Studied Effects in the Literature
- BPC-157 (Pentadecapeptide)BPC-157 Storage, Stability and Reconstitution
- CJC-1295 & IpamorelinIpamorelin Compared With the GHRPs
- Peptide ReferenceHPLC and Mass Spectrometry: What Each Answers
- Bacteriostatic WaterWhy Bacteriostatic Water Is the Default Peptide Diluent
- GLP-1 & Incretin ScienceWhat Fat-Free Mass Actually Contains
- MOTS-c (Mitochondrial Peptide)What Is a Mitochondrial-Derived Peptide?
- Semax (ACTH Fragment Peptide)Is Semax Really an ACTH(4-10) Analogue?
- Selank (Tuftsin Analogue)What Is Tuftsin? An Immunopeptide From Antibody
- DSIP (Delta Sleep-Inducing Peptide)How DSIP Was Discovered
- KLOW (Blend)A Fourfold Size Range in One Vial
- GLOW (Blend)The GHK-Cu Component
- MT-2 (Melanotan II)MT-2 Structure: Four Stability Features in Seven Residues
- IGF-1 LR3IGF-1 LR3 Structure: Three Disulfides and Why They Matter
- GlutathioneThe Gamma-Glutamyl Bond
- NAD+NAD+ Molecular Structure
- KPVKPV Chemical Identity